Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Oral Transmucosal Drugs Market Expected To Grow In Terms Of Size?

The market for oral transmucosal medications has seen robust growth in the past few years. It’s projected to expand from a worth of $39.7 billion in 2024 to $43.21 billion in 2025, with a compound annual growth rate (CAGR) of 8.8%. Factors fueling this growth during the historical period include improvement in diagnostic technologies, older populations, environmental pollution, genetic vulnerability, improved detection rates, quicker relief provided by rapid drug absorption, and superior compliance.

The market for oral transmucosal drugs is predicted to witness substantial growth in the coming years, with the size reaching “$59.89 billion by the year 2029, at a compound annual growth rate (CAGR) of 8.5%. Several factors have been identified as contributing to this expected growth over the forecast period. These include progress in the area of personalized medicine, increasing emphasis on new drug delivery system research, a growing geriatric population, heightened awareness about oral health, the rising demand for non-invasive treatment methods, and changing regulatory frameworks. Furthermore, trends anticipated for the forecast period comprise the use of innovative formulations, implementation of personalized medicine strategies, telehealth developments, the inclusion of digital health technologies and technological breakthroughs in pharmaceuticals.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15627&type=smp

What Market Forces Are Contributing To The Growth Of The Oral Transmucosal Drugs Market?

The oral transmucosal drug market is poised for growth as the occurrences of Parkinson’s disease increases. A neurodegenerative disorder, Parkinson’s disease causes tremors, stiffness, and problems with movement due to a decrease in dopamine-producing cells in the brain. Ageing populations, environmental pollutants, genetic predispositions, and improved diagnostic techniques contributing to higher detection rates have all contributed to an increase in Parkinson’s disease prevalence. Oral transmucosal drugs, which are beneficial in the treatment of Parkinson’s disease, allow for rapid absorption of medication and bypass digestive issues, resulting in quicker relief, improved patient compliance, and potentially fewer motor complications. A report from the Parkinson’s Foundation, a non-profit organization in the US, stated in December 2022 that approximately 1 million people in the US are currently living with Parkinson’s disease. This number is projected to rise to 1.2 million by 2030. As a result, the growing prevalence of Parkinson’s disease is a key driver for the advancement of the oral transmucosal drug market.

What Segmentation Insights Are Provided In The Oral Transmucosal Drugs Market Research?

The oral transmucosal drugs market covered in this report is segmented –

1) By Product Type: Tablets, Films, Liquid And Spray, Other Product Types

2) By Indication: Opioid Dependence, Nausea And Vomiting, Erectile Dysfunction, Neurological Disorders, Other Indications

3) By Route Of Administration: Sublingual Mucosa, Buccal Mucosa, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Tablets: Buccal Tablets, Sublingual Tablets, Effervescent Tablets

2) By Films: Buccal Films, Sublingual Films, Mucoadhesive Films

3) By Liquid And Spray: Sublingual Liquid Solutions, Oral Sprays (Pain Relief, Sleep Aids), Mucosal Gels

4) By Other Product Types: Lozenges, Pastilles, Chewing Gums

Which Notable Trends Are Transforming The Oral Transmucosal Drugs Market Outlook?

Major players in the oral transmucosal drug market are focusing their efforts on creating innovative delivery systems for drugs, such as sublingual vitamin sprays, resulting in improved drug delivery efficiency, enhanced patient comfort, and better therapeutic outcomes. Sublingual vitamin spray is a type of oral transmucosal drug delivery system that delivers vitamins directly into the bloodstream through the mucous membranes found underneath the tongue. The process bypasses the gastrointestinal tract and liver metabolism, ensuring vitamins are absorbed quickly and effectively. For example, Vestige Marketing, a wellness and fitness company from India, launched Absorvit in October 2022. This sublingual vitamin spray ensures quick absorption resulting in faster effects. The product’s innovation enables it to offer absorption rates 3–10 times higher than conventional oral methods. It comprises advanced forms and specific doses of critical vitamins, including B12, C, D, and multivitamins, to ensure the best nutritional delivery possible. Absorvit offers a seamless and productive method of supplementing necessary nutrients, thus improving general health and wellness.

Who Are The Leading Companies Driving The Oral Transmucosal Drugs Market?

Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Oral Transmucosal Drugs Market?

North America was the largest region in the oral transmucosal drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15627&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model